Prior studies have shown the retinoid X receptor (RXR) agonist bexarotene has preventive efficacy in rodent models of mammary and lung tumorigenesis albeit causing hypertriglyeredemia and hypercholesterolemia. We reasoned that bexarotene delivered by inhalation may provide sufficient dose directly to the respiratory tract to achieve efficacy while avoiding these side effects. In this study, the chemopreventive activity of aerosolized-bexarotene was investigated in the benzo(a)pyrene [B(a)P]-induced mouse lung tumor model as assessed by tumor multiplicity and tumor load. Aerosolizedbexarotene significantly decreased tumor multiplicity and tumor load by 43% and 74%, respectively. Our data showed that bexarotene can both inhibit proliferation and promote apoptosis in vivo. Our data also show that aerosolized-bexarotene did not increase plasma total cholesterol and triglyceride level compared with diet group. These results indicate aerosolization may be a safe and effective route of administering bexarotene for chemoprevention of lung cancer.
Introduction
Lung cancer is the leading cause of cancer-related deaths in the United States (1) and one of the most common cancers worldwide. The overall 5-year survival rate is still less than 15% and lung cancer will remain a major health problem in the future. The late presentation of lung cancer symptoms is a major reason for the lack of progress in treatment of this disease. Thus, there is an urgent need to develop improved diagnostic, preventive and therapeutic approaches. Chemoprevention, defined as the administration of natural or synthetic compounds to inhibit, retard, or reverse the process of carcinogenesis, could be an effective approach to reduce the risk of developing cancer (2) (3) (4) . Chemoprevention is also considered to be an important approach to decrease the incidence of lung cancer. 
Bexarotene (Targretin, LG1069), a retinoid X receptor-selective retinoid, is clinically used in the treatment of cutaneous T cell lymphoma and has promising inhibitory effects on lung and mammary tumorigenesis in rodent models (6, 7) . However, bexarotene administration induced hypertriglyceridemia and hypercholesterolemia in both mice and humans (8, 9) . Aerosol drug delivery in lung cancer chemoprevention provides several advantages over systemic delivery including drug delivery directly to the lung with lower doses that produces fewer systemic side effects, and avoidance of first-pass metabolism of the drug in the liver (10) .
In the present study, we investigated the effects of aerosolized-bexarotene on benzo(a)pyrene-induced lung tumorigenesis. We found that aerosolized-bexarotene can inhibit B(a)P-induced lung tumor multiplicity and tumor load. Immunohistochemical Body weight was recorded weekly. The inhalation exposures were conducted using a custom-built nose-only exposure chamber. The mice were exposed to aerosol by placing their noses into the cone of the apparatus. The mice in the air control group were placed in the chamber for 8 min without aerosol treatment to control for potential stress factors affecting tumorigenesis. Mice were euthanized by CO 2 asphyxiation.
Blood samples from the retroorbital plexus of each animal were collected in EDTA- 
Analysis of plasma cholesterol and triglyceride levels
Plasma was collected at the time of killing the mice and placed on ice until centrifuged.
The total cholesterol and triglyceride content of plasma was determined using Infinity Reagent (Thermo DMA, Louisville, MO) according to the manufacturer's protocol.
Analysis of bexarotene concentration in aerosol group and diet group
The concentration of bexarotene in the lungs and plasma of diet or aerosol group was determined by HPLC (15) . A Shimadzu (Kyoto, Japan) Prominence system, consisting of an autosampler, binary pump, temperature controlled column compartment, and UV-VIS detector SPD-20A was used. Liquid chromatographic separations were achieved using an Agilent ZORBAX Eclipse Plus C18 (150 mm × 4.6 mm, 5 ȝm). The mobile phase was made up of methanol (solvent B) and water containing 0.05% NH 4 Ac (solvent A) at a flow rate of 1 mL/min from separate pumps. Buffer B was increased from 0 to 8% by a linear gradient between 0 and 3 min, from 8% to 100% by a linear gradient between 3 and 10 min, maintained at 100% between 10 and 18 min, and 
Statistical Analysis
A one tailed Student's t test was used to test the a priori hypothesis that tumor multiplicity and tumor load were decreased by chemopreventive treatments. Data is presented as mean ± standard deviation. Fig. 2A, 2B, 2E ). There was a significant increase in the number of TUNELpositive cells in the lungs receiving aerosol bexarotene compared with aerosol control mice (Fig. 2C, 2D, 2F Total cholesterol (TC) in the air control, solvent control and aerosol bexarotene were 58.0, 58.5 and 56.7 mg/dL, respectively. In the dietary bexarotene group, the level of TC was 106.7 mg/dL. There was no influence on both plasma TG and TC levels in mice treated with aerosol bexarotene (Figure 3) . In contrast, mice treated with dietary bexarotene showed a 1.7 and 1.8-fold increase in the concentration of triglycerides and total cholesterol, respectively.
Results

Inhibitory
To determine if there is an advantage in delivering bexarotene by aerosol, we compared plasma and lung tissue levels of bexarotene in mice receiving the drug by aerosol or diet. The levels of bexarotene in the lung and plasma were measured by HPLC after aerosol exposure or treatment in the diet. The concentration of bexarotene in lung was 26.2 ȝg/g in aerosol group, and 4.9 ȝg/g in diet group (Fig. 4A) , In plasma, the concentration in the aerosol group and the diet group is 16.5 and 68.4 ȝg/ml, respectively (Fig. 4B) . Furthermore, the ratio of lung/plasma bexarotene has been improved 22 fold by aerosol delivery when compared to that by diet.
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Cancer Research. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research
An ideal chemoprevention agent must be easily tolerated, and cause no significant toxicity or decline in quality of life of high-risk, but otherwise normal individuals (16).
Bexarotene is presently undergoing human phase II and phase III trials in lung cancer and is the first RXR-selective ligand to be tested in humans (17, 18) . It is well tolerated in these trials over a wide dose range (17, 19) . However, bexarotene treatment is associated with side-effects clinically, in particular hypertriglyceridemia (20) and hypercholesterolemia (21) .
Bexarotene has shown to be effective chemopreventive agent in many rodent models including those for lung cancer (6, 22, 23) . Pereira et al. showed that oral gavage of 30 to 300 mg/kg bexarotene reduced the multiplicity of vinyl carbamate-induced mouse lung tumors by 22-33%, furthermore, oral gavage of 100 and 300 mg/kg bexrotene decreased NNK-induced tumor multiplicity by 40-50 % (22) . Its effectiveness by oral delivery was further demonstrated by our group where oral gavage of 180 mg/kg bexrotene significantly decreased small cell lung carcinoma incidence in a lung-specific Rb1 and p53 knockout model (23) . However, and similar to the human situation, bexarotene delivered orally causes hypertriglyceridemia in rodents as well (24 Finding an alternative administration way of bexarotene is urgently needed. In this study, we found that aerosolized-bexarotene could significantly decrease tumor multiplicity and tumor load without increasing plasma triglyceride and cholesterol. When we tested the concentration of bexarotene in lung and plasma, we found that bexarotene concentration in the lung was 5 times higher by using aerosol, and 4 times lower in the plasma. Therefore, aerosol delivery avoids the effects of increased triglyceride and cholesterol levels, which are presumably due to its effects on the liver.
Clearly, aerosol inhalation has the potential advantage of achieving high concentrations of the test agent in the lung with reduced systemic distribution and side effects (26, 27).
We also argue that treatment of mice with a dietary dose of 250 ppm, which roughly equates to the previously described gavage dose of 30 mg/kg, still increases TG levels We show that increased staining by TUNEL assay and decreased staining for Ki-67 in lung tumors from aerosolized-bexarotene treated mice is consistent with a pro-apoptotic effect. Our data suggests that bexarotene can both inhibit proliferation and promote apoptosis within mouse lung tumors and that these mechanisms are likely to contribute to the observed chemopreventive effect.
In summary, the present study indicates that aerosol bexarotene administration can inhibit B(a)P-induced lung tumorigenesis in A/J mice. Aerosol bexarotene administration doesn't cause weight loss or any other observable side effects and does not effect triglyceride or cholesterol levels. Bexarotene also effectively induced apoptosis and decreased proliferation. Therefore, these preclinical observations of aerosolized bexarotene indicate that aerosol delivery may offer significant advantages over oral administration against human lung cancer and provide a basis for future evaluation. 
